• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Verkazia (cyclosporine ophthalmic emulsion, 0.1%)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Verkazia (cyclosporine ophthalmic emulsion, 0.1%)

  • Profile

Profile

Contact Information

Contact: Santen Pharmaceuticals
Website: https://www.santenusa.com/

Currently Enrolling Trials

    Show More

    General Information

    Verkazia (cyclosporine ophthalmic emulsion) 0.1% is a calcineurin inhibitor immunosuppressant.

    Verkazia is specifically indicated for the treatment of vernal keratoconjunctivitis (VKC) in children and adults.

    Verkazia is supplied as an emulsion for topical ophthalmic use. 

    General Dosing Information

    • Gently shake the single-dose vial several times to obtain a uniform, white, opaque emulsion before use.
    • Contact lenses should be removed before applying Verkazia and may be reinserted 15 minutes after administration.
    • If a dose is missed, treatment should be continued as normal, at the next scheduled administration.
    • If more than one topical ophthalmic product is being used, administer the eye drops at least 10 minutes apart to avoid diluting products.
    • Administer Verkazia 10 minutes prior to using any eye ointment, gel or other viscous eye drops. Discard the vial immediately after use.

    Recommended Dosage and Dose Administration

    • Instill one drop of Verkazia, 4 times daily (morning, noon, afternoon, and evening) into each affected eye.
    • Treatment can be discontinued after signs and symptoms are resolved and can be reinitiated if there is a recurrence

    Mechanism of Action

    Verkazia (cyclosporine ophthalmic emulsion) 0.1% is a calcineurin inhibitor immunosuppressant agent when administered systemically. Following ocular administration, cyclosporine is thought to act by blocking the release of pro-inflammatory cytokines such as IL-2. The exact mechanism of action in the treatment of VKC is not known.

    Side Effects

    Adverse effects associated with the use of Verkazia may include, but are not limited to, the following:

    • eye pain
    • eye pruitis

    Clinical Trial Results

    The FDA approval of Verkazia was based on two randomized, multi-center, double-masked, vehicle-controlled, clinical trials (VEKTIS Study and NOVATIVE Study). In the VEKTIS study, patients with severe VKC were randomized to four times daily of Verkazia 1 mg/mL or two times daily (BID) of Verkazia 1 mg/mL and vehicle group for the first 4 months (Period 1). In the NOVATIVE study, patients with moderate to severe VKC were randomized to QID of Verkazia 1 mg/mL or QID of cyclosporine ophthalmic emulsion 0.5 mg/mL and vehicle group for the first 1 month (Period 1). In both studies, patients randomized to the vehicle group were switched to Verkazia (QID or BID) from Month 4 to Month 12 in VEKTIS Study and to cyclosporine ophthalmic emulsion 0.5 mg/mL QID or 1 mg/mL from Month 1 to Month 4 in NOVATIVE Study (Period 2). In both studies, Verkazia demonstrated improvements in inflammation of the cornea (keratitis score) and ocular itching. 

    Approval Date: 2021-06-01
    Company Name: Santen Pharmaceuticals
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Revamp-360x240.png

      Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

    • AskTheExpertsGreen-360x240.png

      Ask the Experts: Managing Investigational Products

    • SurveywBlueBackground-360x240.png

      Survey Outlines Site Challenges, Successes on Diversity

    • PatientCentricity-360x240.png

      Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing